OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral
fluid diagnostics, today announced quarterly revenues of $16.9
million for the three months ended September 30, 2008, compared to
$21.4 million in revenues for the three months ended September 30,
2007. Sales of the Company�s OraQuick ADVANCE� rapid HIV-1/2
antibody test increased 18% for the third quarter 2008. This
increase was offset primarily by an expected decrease in sales of
the Company�s over-the-counter (�OTC�) cryosurgical products. The
Company�s net loss was $1.8 million, or $0.04 per share for the
third quarter of 2008, compared to net income of $4,000 and
break-even earnings per share for the third quarter of 2007. This
decrease was primarily caused by reduced sales in the current
quarter. �Sales of our OraQuick ADVANCE� rapid HIV test were strong
during the current quarter, and we have taken steps to drive
stronger sales performance in our other product lines,� said
Douglas A. Michels, President and CEO of OraSure Technologies. �As
previously announced, we are terminating our distribution agreement
with Abbott Laboratories and will begin selling OraQuick ADVANCE�
directly to U.S. hospitals in 2009. We expect our OraQuick�
business will continue to grow with the transition to this direct
sales model. We also continue to make great progress against our
strategic objectives, the most significant of which was the recent
submission of a pre-market approval application to the FDA for our
OraQuick� HCV test.� For the nine months ended September 30, 2008,
the Company recorded revenues of $53.9 million, a decrease of 14%
when compared to revenues of $62.9 million for the nine months
ended September 30, 2007. The Company recorded a net loss of $2.0
million or $0.04 per share, for the nine months ended September 30,
2008, compared to net income of $2.4 million, or $0.05 per share on
a fully-diluted basis, for the nine months ended September 30,
2007. Gross margin in both the third quarter and the nine months
ended September 30, 2008 was 58% compared with 60% in the third
quarter of 2007 and 62% in the nine months ended September 30,
2007. Margins in the current periods were primarily impacted by an
unfavorable product mix. Operating expenses for the third quarter
of 2008 decreased $670,000 to $13.1 million, from $13.7 million in
the comparable period in 2007 primarily due to lower legal costs in
the current three-month period. Operating expenses for the nine
months ended September 30, 2008 were $41.7 million, compared to
$38.5 million for the comparable period in 2007. The increase in
year-to-date operating expenses is attributable to higher research
and development costs associated with the Company�s OraQuick� HIV
OTC and OraQuick� HCV clinical development programs, partially
offset by a decline in general and administrative expenses largely
due to decreased legal costs. Cash, cash equivalents and short-term
investments were $85.4 million and working capital was $99.5
million at September 30, 2008, compared to $95.6 million and $105.6
million, respectively, at December 31, 2007. Cash flow used in
operating activities for the nine months ended September 30, 2008
was $3.7 million compared to $7.8 million provided by operations
for the comparable period in 2007. During the third quarter of
2008, the Company purchased $3.1 million of stock under its
previously announced stock repurchase plan. Fourth Quarter and Full
Year 2008 Outlook The Company expects revenues of $16.0 to $16.5
million in the fourth quarter of 2008 with a loss per share of
approximately $0.10. Included in the loss per share are charges
associated with the transition of hospital and other business under
the agreement with Abbott Laboratories and a $1.0 million charge
associated with a milestone payment related to the filing of a
pre-market approval application with the FDA for the Company�s
OraQuick� HCV test. � � � � Financial Data � Condensed Financial
Data (In thousands, except per-share data and percentages) �
Unaudited � Three months ended Nine months ended September 30,
September 30, 2008 2007 2008 2007 Results of Operations Revenues $
16,860 $ 21,415 $ 53,895 $ 62,877 Cost of products sold � 7,145 � �
8,647 � � 22,393 � � 24,122 Gross profit � 9,715 � � 12,768 � �
31,502 � � 38,755 Operating expenses: Research and development
4,167 3,672 14,864 9,896 Sales and marketing 5,327 4,979 15,505
14,999 General and administrative � 3,562 � � 5,074 � � 11,293 � �
13,637 Total operating expenses � 13,056 � � 13,725 � � 41,662 � �
38,532 Operating income(loss) (3,341 ) (957 ) (10,160 ) 223 Other
income, net 588 1,085 7,078 4,443 Income tax provision (benefit) �
(991 ) � 124 � � (1,079 ) � 2,221 Net income (loss) $ (1,762 ) $ 4
� $ (2,003 ) $ 2,445 Earnings (loss) per share: Basic and Diluted $
(0.04 ) $ - � $ (0.04 ) $ 0.05 � Weighted average shares: Basic �
46,692 � � 46,341 � � 46,774 � � 46,393 Diluted � 46,692 � � 46,988
� � 46,774 � � 46,893 � � Three months ended September 30, Dollars
� % Change � Percentage of Total Revenues Market Revenues 2008 �
2007 2008 � 2007 � Infectious disease testing $ 9,743 $ 8,233 18 %
58 % 38 % Substance abuse testing 3,581 4,070 (12 ) 21 19
Cryosurgical systems 1,671 6,738 (75 ) 10 31 Insurance risk
assessment � 1,163 � � 1,620 � (28 ) 7 � 8 � Product revenues
16,158 20,661 (22 ) 96 96 Licensing and product development � 702 �
� 754 � (7 ) 4 � 4 � Total revenues $ 16,860 � $ 21,415 � (21 )%
100 % 100 % � � � � Nine months ended September 30, Dollars %
Change Percentage of Total Revenues Market Revenues 2008 2007 2008
2007 � Infectious disease testing $ 29,260 $ 26,350 11 % 54 % 42 %
Substance abuse testing 10,554 12,396 (15 ) 20 20 Cryosurgical
systems 7,726 18,190 (58 ) 14 29 Insurance risk assessment � 4,395
� � 3,859 � 14 8 � 6 � Product revenues 51,935 60,795 (15 ) 96 97
Licensing and product development � 1,960 � � 2,082 � (6 ) 4 � 3 �
Total revenues $ 53,895 � $ 62,877 � (14 )% 100 % 100 % � � � � � �
� Three months ended Nine months ended September 30, % Change
September 30, % Change OraQuick� Revenues 2008 2007 2008 2007 �
Direct to U.S. Public Health $ 6,147 $ 4,492 37 % $ 19,263 $ 14,339
34 % Abbott 1,799 2,159 (17 ) 5,489 6,087 (10 ) SAMHSA/CDC 10 30
(67 ) 10 1,464 (99 ) International � 957 � � 850 � 13 � 2,303 � �
2,110 � 9 Total OraQuick� revenues $ 8,913 � $ 7,531 � 18 % $
27,065 � $ 24,000 � 13 % � � � Three months ended Nine months ended
September 30, % Change September 30, % Change Intercept� Revenues
2008 2007 2008 2007 � Workplace testing $ 1,193 $ 1,845 (35 )% $
3,480 $ 5,368 (35 )% Criminal Justice 637 641 (1 ) 1,965 1,948 1
International 481 525 (8 ) 1,570 1,757 (11 ) Direct � 303 � � 273 �
11 � 904 � � 739 � 22 Total Intercept� revenues $ 2,614 � $ 3,284 �
(20 )% $ 7,919 � $ 9,812 � (19 )% � � � Three months ended Nine
months ended � September 30, % Change September 30, % Change
Cryosurgical Systems Revenues 2008 2007 2008 2007 � Professional
domestic $ 903 $ 1,028 (12 )% $ 2,942 $ 3,441 (15 )% Professional
international 401 574 (30 ) 1,802 1,551 16 OTC domestic ? 2,453
(100 ) ? 5,587 (100 ) OTC international � 367 � � 2,683 � (86 ) �
2,982 � � 7,611 � (61 ) Total cryosurgical systems revenues $ 1,671
� $ 6,738 � (75 )% $ 7,726 � $ 18,190 � (58 )% � � Unaudited
Balance Sheets September 30, 2008 � December 31, 2007 Assets Cash,
cash equivalents and short-term investments $ 85,382 $ 95,566
Accounts receivable, net 12,381 11,296 Inventories 10,238 9,410
Current portion of deferred income taxes 2,676 5,061 Other current
assets 1,193 2,456 Property and equipment, net 21,373 20,911
Deferred income taxes 21,108 17,266 Other non-current assets �
4,668 � 5,387 Total assets $ 159,019 $ 167,353 � Liabilities and
Stockholders� Equity Current portion of long-term debt $ 558 $ 557
Accounts payable 2,534 5,616 Accrued expenses 9,228 11,995
Long-term debt 8,441 8,818 Other liabilities 11 312 Stockholders�
equity � 138,247 � 140,055 Total liabilities and stockholders�
equity $ 159,019 $ 167,353 � � � As of September 30, Additional
Financial Data 2008 2007 Capital expenditures $ 1,949 $ 4,281
Depreciation and amortization $ 2,122 $ 1,997 Purchase and
retirement of common stock $ 3,052 ? Accounts receivable � days
sales outstanding 63 days 52 days � Conference Call The Company
will host a conference call and audio webcast today to discuss the
Company's 2008 third quarter financial results, business
developments and the Company�s 2008 fourth quarter outlook,
beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). On
the call will be Douglas A. Michels, President and Chief Executive
Officer, and Ronald H. Spair, Chief Operating Officer and Chief
Financial Officer. The call will include remarks by management and
a question and answer session. In order to listen to the conference
call, please dial 888-742-2024 (Domestic) or 706-643-0033
(International) and reference 69750537 or go to OraSure
Technologies� web site, www.orasure.com, and click on the Investor
Info link. A replay of the call will be archived on OraSure
Technologies' web site shortly after the call has ended and will be
available for seven days. A replay of the call can also be accessed
until November 11, 2008, by dialing 800-642-1687 (Domestic) or
706-645-9291 (International) and entering the Conference ID
#69750537. About OraSure Technologies OraSure Technologies
develops, manufactures and markets oral fluid specimen collection
devices and tests and other diagnostic products using proprietary
technologies, including immunoassays and other in vitro diagnostic
tests and other medical devices. These products are sold in the
United States and certain foreign countries to clinical
laboratories, hospitals, clinics, community-based organizations and
other public health organizations, distributors, government
agencies, physicians� offices, and commercial and industrial
entities. For more information on the Company, please visit
www.orasure.com. Important Information This press release contains
certain forward-looking statements, including with respect to
revenues, expenses, net income, earnings/loss per share and
products. Actual results could be significantly different. Factors
that could affect results include the ability to market and sell
products; changes in relationships, including disputes or
disagreements, with strategic partners and reliance on strategic
partners for the performance of critical activities under
collaborative arrangements; failure of distributors or other
customers to meet purchase forecasts or minimum purchase
requirements for the Company�s products; impact of replacing
distributors; inventory levels at distributors and other customers;
impact of replacing distributors; inventory levels at distributors
and other customers; impact of competitors, competing products and
technology changes; ability to develop, commercialize and market
new products; market acceptance of oral fluid testing or other
products; changes in market acceptance of products based on product
performance; continued bulk purchases by customers, including
governmental agencies, and the ability to fully deploy those
purchases in a timely manner; ability to fund research and
development and other products and operations; ability to obtain
and maintain new or existing product distribution channels;
reliance on sole supply sources for critical product components;
availability of related products produced by third parties or
products required for use of our products; ability to obtain, and
timing and cost of obtaining, necessary regulatory approvals for
new products or new indications or applications for existing
products; ability to comply with applicable regulatory
requirements; history of losses and ability to achieve sustained
profitability; volatility of the Company�s stock price; uncertainty
relating to patent protection and potential patent infringement
claims; uncertainty and costs of litigation relating to patents and
other intellectual property; availability of licenses to patents or
other technology; ability to enter into international manufacturing
agreements; obstacles to international marketing and manufacturing
of products; ability to sell products internationally, including
changes in international funding sources; loss or impairment of
sources of capital; ability to meet financial covenants in
agreements with financial institutions; ability to retain qualified
personnel; exposure to patent infringement, product liability, and
other types of litigation; changes in international, federal or
state laws and regulations; customer consolidations and inventory
practices; equipment failures and ability to obtain needed raw
materials and components; the impact of terrorist attacks and civil
unrest; ability to identify, complete and realize the full benefits
of potential acquisitions; and general political, business and
economic conditions. These and other factors are discussed more
fully in the Securities and Exchange Commission (�SEC�) filings of
OraSure Technologies, including its registration statements, its
Annual Report on Form 10-K for the year ended December 31, 2007,
its Quarterly Reports on Form 10-Q, and its other filings with the
SEC. Although forward-looking statements help to provide complete
information about future prospects, readers should keep in mind
that forward-looking statements may not be reliable. The
forward-looking statements are made as of the date of this press
release and OraSure Technologies undertakes no duty to update these
statements.
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Lug 2023 a Lug 2024